Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology
Лёгочная артериальная гипертензия и хроническая тромбоэмболическая лёгочная гипертензия: патофизиология
2010-02-28
SCID: 54.1/fzum2s74
Discuss with AI
BMPR2 mutationschronic thromboembolic pulmonary hypertensionendothelial cell dysfunctionpulmonary arterial hypertensionpulmonary endarterectomy
Figures from the paper
Abstract (AI)
Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are two of the key subgroups of pulmonary hypertension. They are characterised by different risk factors. PAH can be associated with mutations in the gene encoding bone morphogenetic protein receptor type II (BMPR2), HIV infection, congenital heart disease, connective tissue disease (such as systemic sclerosis), and exposure to particular drugs and toxins including fenfluramine derivatives. In contrast, CTEPH can be associated with anti-phospholipid antibodies, splenectomy and the presence of a ventriculo-atrial shunt or an infected pacemaker. The first-line therapies used to treat PAH and CTEPH also differ. While medical therapy tends to be used for patients with PAH, pulmonary endarterectomy is the treatment of choice for patients with CTEPH. However, there are possible common mechanisms behind the two diseases, including endothelial cell dysfunction and distal pulmonary artery remodelling. Further research into these similarities is needed to assist the development of targeted pharmacological therapies for patients with inoperable CTEPH and patients who have persistent pulmonary hypertension after endarterectomy.
Key Findings
1
CTEPH is associated with anti-phospholipid antibodies, splenectomy, and ventriculo-atrial shunts or infected pacemakers.
2
Endothelial dysfunction and distal pulmonary artery remodeling may represent shared mechanisms, motivating targeted drug development for inoperable CTEPH and persistent post-endarterectomy pulmonary hypertension.
3
First-line treatments differ: medical therapy is generally used for PAH, whereas pulmonary endarterectomy is preferred for CTEPH.
4
PAH and CTEPH are distinct pulmonary hypertension subgroups with different associated risk factors.
5
PAH is associated with BMPR2 mutations, HIV infection, congenital heart disease, connective tissue disease, and exposure to fenfluramine derivatives and other toxins.
Research Object
Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH)
Research Subject
Their distinct risk factors, pathophysiology, and shared mechanisms, including endothelial cell dysfunction and distal pulmonary artery remodelling
Publication Details
Publication Date
2010-02-28
Journal
Publisher
ISSN
Cited by
159
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest